Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

TH QUARTER ENDED DECEMBER 31, 2007

Consolidated revenues were $10.2 million for the fourth quarter ended December 31, 2007 compared to $11.9 million for the same quarter in 2006. The decrease in revenues is attributable to lower sales of Impavido(R), as well as active pharmaceutical ingredients to the Company's partners, combined with lower license fees from the Company's partners.

Selling, General and Administrative (SG&A) expenses were $5.1 million for the fourth quarter ended December 31, 2007 compared to $4.2 million for the same quarter in 2006. The increase in SG&A is mainly related to the support of the continuation of a Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH) and the opening of a new operational headquarters in New Jersey.

Consolidated Research & Development (R&D) expenses were $13.6 million for the fourth quarter ended December 31, 2007 compared to $7.9 million for the same quarter in 2006. The increase in R&D expenses relates to the continuation of the Company's Phase 3 program with cetrorelix in BPH.

Consolidated net loss was $13.6 million or $0.26 per basic and diluted share for the fourth quarter ended December 31, 2007 compared to consolidated net earnings of $39.1 million or $0.74 per basic and diluted share for the same quarter in 2006. The increased net loss in the fourth quarter 2007 is related to higher loss from operations of nearly $5.2 million mainly related to increased R&D expenses, as well as to lower income tax recovery of nearly $28.4 million attributable to the recognition of future income tax assets mainly related to the sale of Atrium shares in 2006 and the special distribution of the Company's remaining interest in January 2007, combined with the decrease in net earnings from Atrium's discontinued operations of approximately $16.3 million.

The consolidated cash and short-term investments were $41.4 million as of December 31, 2007.

CONSOLIDATED RESULTS FOR THE FULL
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... -- , A major pan-European survey into ... of care has revealed changing trends in many important ... provision of healthcare services across the continent. The results ... Gastroenterology (UEG), have been announced today and led to ... burden of GI disorders across Europe ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... CAMBRIDGE, Mass. , Oct. 19, 2014 NextCODE ... of the whole genome in real time, today announced the ... the NextCODE Exchange , at the American Society of ... . To learn more, sign up and apply for ... on its unique features and benefits can be viewed ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... petroleum-based energy production. However, current solar-cell technology often does ... expensive to mass-produce. In addition, information on the total ... incomplete, experts say. To better understand the energy ... research team from Rochester Institute of Technology has conducted ...
... Belgium and BOSTON, September 17, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... A new technology for removing water from ultrafine coal ... at an operating coal cleaning plant. The technology offers ... from the source. A peer-reviewed paper on this new ... Coal Preparation Society Conference, Cairns, Queensland. Cleaning coal ...
Cached Biology Technology:Research team assesses environmental impact of organic solar cells 2Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 2Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 3Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 4Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 5Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 6Materialise and Dr. J.B. Jupiter Explore the Power of Virtual Surgical Planning in Correcting Compound Wrist Fractures 7Commercial-scale test of new technology to recover coal from sludge successful 2Commercial-scale test of new technology to recover coal from sludge successful 3
(Date:10/16/2014)... Post-menopausal women experienced improvements in vaginal atrophy, with ... bleeding, after 12 weeks of daily 10 milligram ... nutritional supplement previously shown to help relieve certain ... study reported in a poster at the North ... , "These data documented improved vaginal epithelium, without ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... are improving the taste, appearance and nutritional content of ... grow to $6 billion by 2017, according to a ... (IFT) Annual Meeting & Food Expo in Chicago. ... an immune disorder triggered by the ingestion of gluten ...
... tissue sustains irreparable damage in the wake of a ... and the cardiac muscle contains few stem cells, the ... fibrotic and cannot contract properly. In their search ... been exploring cardiac "patches" that could be transplanted into ...
... to cancer and other diseases, genetic testing, infectious proteins ... topics internationally renowned speakers will tackle at The EMBO ... from 21-24 September 2013. Sir Michael Stratton, Director ... Executive Officer of deCODE Genetics, and Thijn Brummelkamp, Group ...
Cached Biology News:New technologies and ingredients provide better options for gluten-free eating 2A heart of gold 2Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam 2
Mouse Cell Line Slides...
Human Cell Line Slides...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: